Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP7 | P09237 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL27706425 | 0.96 | ACE (0.59) | ACELTA4HITGB3ITGA2BMMP2 | |
| Leucine SCHEMBL10531667 | 0.89 | LTA4H (0.58) | ACELTA4H | |
| D-Phenylalanine SCHEMBL8498797 | 0.85 | ACE (0.50) | ACELTA4HITGB3ITGA2B | |
| SCHEMBL233942 | 0.84 | ACE (0.56) | ACEITGB3ITGA2BMMP2MMP7 | |
| Leucine SCHEMBL15689579 | 0.84 | PSMB5 (0.57) | ACELTA4HPSMB5 | |
| SCHEMBL4153095 | 0.83 | ITGB3 (0.65) | ACEITGB3ITGA2BPIN1 | |
| SCHEMBL4153101 | 0.83 | ITGB3 (0.65) | ACEITGB3ITGA2BPIN1 | |
| SCHEMBL5458748 | 0.83 | ITGB3 (0.65) | ACEITGB3ITGA2BPIN1 | |
| SCHEMBL15345879 | 0.82 | LTA4H (0.62) | ACELTA4HMMP2MMP7MMP9 | |
| SCHEMBL8078351 | 0.81 | MME (0.58) | ACELTA4HPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | US | claimed |
| EP-1627880-A1 | Boronic ester and acid compounds, synthesis and uses | Millennium Pharmaceuticals, Inc. (US) | 2006-02-22 | — | — | EP | claimed |
| EP-1312609-A1 | Boronic ester and acid compounds, synthesis and uses | Millennium Pharmaceuticals, Inc. (US) | 2003-05-21 | — | — | EP | claimed |
| EP-0788360-A4 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT INC (US) | 1998-05-06 | — | — | EP | claimed |
| EP-0788360-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1997-08-13 | — | — | EP | claimed |
| WO-1996013266-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1996-05-09 | — | — | WO | claimed |
| US-20210177928-A1 | Method of Reducing Titers of Antibodies Specific for a Therapeutic Agent | DUKE UNIVERSITY | 2021-06-17 | — | — | US | disclosed |
| US-20210106522-A1 | INTRATUMORAL DELIVERY OF BORTEZOMIB | COGNOS THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-10869906-B2 | Method of reducing titers of antibodies specific for a therapeutic agent | DUKE UNIVERSITY (US) | 2020-12-22 | — | — | US | disclosed |
| CN-111867573-A | Intratumoral delivery of bortezomib | 科诺斯治疗学公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200323889-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-10-15 | — | — | US | disclosed |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-02-13 | — | — | US | disclosed |
| EP-3566719-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | Cerulean Pharma Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-6297217-B1 | TREATMENT OF CANCER WITH PROTEASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2001-10-02 | — | — | US | disclosed |
| US-6083903-A | REDUCE RATE OF DEGRADATION OF PROTEINS IN ANIMAL | LEUKOSITE, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| US-6066730-A | Boronic ester and acid compounds, synthesis and uses | PROSCRIPT, INC. | 2000-05-23 | — | — | US | disclosed |
| US-5780454-A | Boronic ester and acid compounds | PROSCRIPT, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0788360-A4 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT INC (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0788360-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996013266-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | ACE 2375/4885LTA4H 2755/4885ITGB3 3002/4885 |
| US-20200323889-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | ACE 1596/4885LTA4H 3845/4885ITGB3 2282/4885 |
| US-10869906-B2 | Method of reducing titers of antibodies specific for a therapeutic agent | SNRPE, SARNP, RBM17 | ACE 894/4885LTA4H 2250/4885ITGB3 1305/4885 |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | ACE 2691/4885LTA4H 2717/4885ITGB3 3553/4885 |
| US-20210177928-A1 | Method of Reducing Titers of Antibodies Specific for a Therapeutic Agent | SNRPE, SARNP, RBM17 | ACE 894/4885LTA4H 2250/4885ITGB3 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.